Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8740420 | Journal of Infection | 2018 | 6 Pages |
Abstract
In conclusion, our data demonstrate that less than half of these patients receiving standardized second-line treatment regimen meet the definition of successful treatment during a 3-year period in China. More attention should be paid to the MDR-TB population at high-risk of poor clinical outcome, including male, elderly age, and those who have received prior treatment.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Caihong Xu, Yu Pang, Renzhong Li, Yunzhou Ruan, Lixia Wang, Mingting Chen, Hui Zhang,